AAPP supports the use of antipsychotics as the first line treatment for acute and maintenance treatment of schizophrenia, with individual agent and route of administration selected based on patient-specific factors. Psychiatric pharmacists are encouraged to use this policy brief to support your own advocacy for this gold-standard treatment.